Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer
PCa cell subpopulation dynamics and credentials BCL-2 as a vital therapeutic target in heterogeneous CRPC.
Authors
- Amanda Tracz
- Kent L. Nastiuk
- Changmeng Cai (ORCID: https://orcid.org/0000-0002-8701-2586)
- Jason Kirk
- Anmbreen Jamroze (ORCID: https://orcid.org/0009-0006-0444-820X)
- Justine J. Jacobi (ORCID: https://orcid.org/0000-0002-9109-3294)
- Kevin Lin (ORCID: https://orcid.org/0000-0002-1236-9847)
- Dean G. Tang (ORCID: https://orcid.org/0000-0001-5029-1174)
- Surui Hou
- Igor Puzanov
- Han Yu
- Xin Chen
- Jiaoti Huang
- Xiaozhuo Liu
- Qiuhui Li
- Gurkamal Chatta
- Wen Jess Li
- Mingyu Liu
- Yue Lu
Institutions
- Cedars-Sinai Medical Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Duke University (US)
- University of Massachusetts Boston (US)
- Wuhan University (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Signal Transduction and Targeted Therapy
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1038/s41392-026-02700-w
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Prostate Cancer Foundation
- Roswell Park Alliance Foundation, Roswell Park Cancer Institute
- National Cancer Institute